Turning Point Brands delivered a strong second quarter in 2025, with total consolidated net sales increasing by 25.1% year-over-year to $116.6 million. This growth was largely fueled by an exceptional 651% increase in Modern Oral net sales, which reached $30.1 million. The company also saw a substantial rise in gross profit and adjusted EBITDA, leading to improved diluted EPS and adjusted diluted EPS.
Total consolidated Net Sales increased 25.1% year-over-year to $116.6 million.
Modern Oral Net Sales surged by 651% to $30.1 million, now representing 26% of total Net Sales.
Adjusted EBITDA grew by 14.8% to $30.5 million, exceeding prior year performance.
The company raised its full-year 2025 Adjusted EBITDA guidance to $110.0 β 114.0 million and Modern Oral sales guidance to $100.0 β 110.0 million.
Turning Point Brands is increasing its full-year 2025 guidance for both Adjusted EBITDA and consolidated Modern Oral sales, reflecting confidence in continued strong performance.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance